Gilead Sciences (GILD) Invested Capital (2009 - 2026)

Gilead Sciences (GILD) has 18 years of Invested Capital data on file, last reported at $45.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 3.77% year-over-year to $45.7 billion; the trailing twelve-month figure through Mar 2026 stood at $45.7 billion (up 3.77% YoY), and the FY2025 full-year result was $47.6 billion, up 3.66% from the prior year.
• Invested Capital for Q1 2026 stood at $45.7 billion, down from $47.6 billion in the prior quarter.
• Across five years, Invested Capital topped out at $47.7 billion in Q4 2023 and bottomed at $41.5 billion in Q2 2024.
• The 5-year median for Invested Capital is $46.2 billion (2023), against an average of $45.5 billion.
• The widest annual swing landed in 2024, when Invested Capital decreased 11.83%; it then grew 11.63% in 2025.
• A 5-year view of Invested Capital shows it stood at $46.4 billion in 2022, then gained by 2.8% to $47.7 billion in 2023, then fell by 3.73% to $46.0 billion in 2024, then gained by 3.66% to $47.6 billion in 2025, then dropped by 4.1% to $45.7 billion in 2026.
• The last three Invested Capital figures came in at $45.7 billion (Q1 2026), $47.6 billion (Q4 2025), and $46.5 billion (Q3 2025), per Business Quant data.

Peer Comparison